Valuation: Bavarian Nordic A/S

Capitalization 15.42B 2.44B 2.06B 1.9B 1.8B 3.33B 225B 3.39B 22.23B 8.72B 109B 9.14B 8.95B 385B P/E ratio 2026 *
27.1x
P/E ratio 2027 * 19.6x
Enterprise value 11.74B 1.85B 1.57B 1.45B 1.37B 2.53B 172B 2.58B 16.93B 6.64B 83.17B 6.96B 6.81B 293B EV / Sales 2026 *
2.21x
EV / Sales 2027 * 1.96x
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -
1 day+0.60%
1 week+1.42%
Current month+3.70%
1 month+8.30%
3 months+0.53%
6 months-15.88%
Current year+4.90%
1 week 194.8
Extreme 194.8
203.2
1 month 182.5
Extreme 182.5
203.2
Current year 175.5
Extreme 175.5
203.2
1 year 142.35
Extreme 142.35
244.8
3 years 123.3
Extreme 123.3
300
5 years 115.2
Extreme 115.2
411
10 years 103.2
Extreme 103.2
444
Manager TitleAgeSince
Chief Executive Officer 59 28/05/2014
Director of Finance/CFO 61 01/11/2018
Chief Operating Officer 58 01/04/2022
Director TitleAgeSince
Director/Board Member 63 20/04/2016
Chairman 63 13/11/2025
Director/Board Member 46 01/01/2021
Change 5d. change 1-year change 3-years change Capi.($)
+0.60%+1.42%+32.01%+2.09% 2.44B
+2.55%-1.32%+10.37%+148.97% 830B
-0.15%-1.79%+48.71%+41.35% 564B
-0.29%+0.21%+20.46%+29.28% 369B
-0.35%0.00%+23.47%+13.55% 328B
+1.72%-0.74%+49.33%+27.86% 318B
+1.19%-2.41%+31.10%+34.87% 291B
+3.13%-1.94%+52.65%+3.53% 294B
+1.69%+1.22%+28.13%+43.23% 192B
+1.24%+8.21%-38.18%-55.23% 182B
Average +1.13%+0.11%+25.81%+28.95% 337B
Weighted average by Cap. +1.24%-0.78%+26.72%+53.53%

Financials

2026 *2027 *
Net sales 5.32B 840M 712M 655M 620M 1.15B 77.77B 1.17B 7.67B 3.01B 37.7B 3.15B 3.09B 133B 5.57B 879M 745M 685M 648M 1.2B 81.34B 1.22B 8.02B 3.15B 39.43B 3.3B 3.23B 139B
Net income 582M 92.01M 77.94M 71.71M 67.87M 126M 8.51B 128M 840M 329M 4.13B 345M 338M 14.55B 806M 127M 108M 99.27M 93.95M 174M 11.79B 177M 1.16B 456M 5.71B 478M 468M 20.13B
Net Debt -3.68B -581M -493M -453M -429M -795M -53.81B -809M -5.31B -2.08B -26.08B -2.18B -2.14B -91.93B -4.52B -714M -605M -556M -526M -976M -66.03B -993M -6.51B -2.55B -32.01B -2.68B -2.62B -113B
Logo Bavarian Nordic A/S
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (97,2%) and services (2,8%). Net sales are distributed geographically as follows: the United States (43.2%), Germany (18.6%), France (11.6%), Canada (3.6%), THE United Kingdom (3.4%), Finland (2.9%), Singapore (2.2%), Switzerland (1.7%), Australia (1.3%), Saudi Arabia (1.2%), Spain (0.6%), and others (9.7%).
Employees
1,692
Date Price Change Volume
17/04/26 200.20 kr +0.60% 226,241
16/04/26 199.00 kr -0.80% 210,271
15/04/26 200.60 kr +0.30% 211,275
14/04/26 200.00 kr +0.91% 300,472
13/04/26 198.20 kr +0.41% 91,174
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
200.20DKK
Average target price
268.33DKK
Spread / Average Target
+34.03%

Quarterly revenue - Rate of surprise